De Novo device
Vibrant System
Vibrant, Ltd. · Orally Ingested Transient Device For Constipation (QTN, Class II) · First FDA decision Aug 26, 2022, newest Dec 8, 2023Fecal incontinence and constipation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
De Novo pathway
Device trials
22
Naming "Vibrant"
MAUDE reports
700
Brand "Vibrant", since 2015
PubMed studies
2,641
Mentioning "Vibrant"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Vibrant System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Vibrant System510(k)
K232830 · Decided Dec 8, 2023 · 86 days after receipt
Device type: Orally Ingested Transient Device For Constipation (QTN) · GI, Urology & Nephrology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Vibrant", any status and sponsor, newest update first.
- Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low BackPaiN Treatment: VIBRANTPivotal-lookingNot yet recruiting
VA Office of Research and DevelopmentFederal agency
NCT07158567 · 213 participants (planned) · Start Oct 30, 2026 · Primary completion Jun 1, 2031
Device: intermittent theta burst stimulation · For: Chronic Low Back Pain; Musculoskeletal Pain
Sites: Chicago, Illinois; Hines, Illinois
21 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Vibrant", and for the whole product code for context.
This brand
700 reports: 320 malfunction, 378 injury, 0 death
Whole product code QTN
36 reports: 9 malfunction, 27 injury, 0 death
Newest reports for this brand
- Vibrant SoundbridgeInjury
MED-EL Elektromedizinische Geraete GmbH
9710014-2026-00995 · Received Oct 28, 2026 · Event dated Jun 21, 2026
Device type: Implant, Hearing, Active, Middle Ear, Partially Implanted (MPV)
Device problem as coded: No Device Output
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Vibrant"[tiab]. The summary above synthesizes these.
- Pounds.
Gianakos D · Ann Fam Med · 2004
- Huntington's Disease Clinical Trials Corner: March 2024.
Estevez-Fraga C, Tabrizi SJ, Wild EJ · J Huntingtons Dis · 2024Research Support, Non-U.S. Gov't
- Innovation and Invention.
Carr E · Clin J Oncol Nurs · 2019Editorial
- Freeform optics: introduction.
Falaggis K, Rolland J, Duerr F, et al. · Opt Express · 2022
- VIBRANT: spectral profiling for single-cell drug responses.
Liu X, Shi L, Zhao Z, et al. · Nat Methods · 2024
- Geroscience and Its Promise.
Olshansky SJ, Kirkland JL · Cold Spring Harb Perspect Med · 2024Review
- [To construct Chinese hematology community].
Huang XJ, Xu ZL · Zhonghua Xue Ye Xue Za Zhi · 2024
- Homogeneous Gold-Catalyzed Oxidation Reactions.
Zheng Z, Ma X, Cheng X, et al. · Chem Rev · 2021Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.
- Advances in auditory implants.
Iwasaki S · Auris Nasus Larynx · 2023Review
- The Vibrant Soundbridge: A Global Overview.
Maw J · Otolaryngol Clin North Am · 2019Review
- Why Japan lacks a vibrant biotech industry.
Kessel M, Vickrey C · Nat Biotechnol · 2024Letter
- Bionic ear imaging.
Cerini R, Faccioli N, Barillari M, et al. · Radiol Med · 2008Comparative Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.